Key points
- Ella Marchant, a 27‑year‑old clinical pharmacist from Hampstead Garden Suburb in North London, will run the TCS London Marathon on Sunday, April 26, 2026.
- She is running in memory of her uncle, Greville Marchant, who lived in Hendon and died in June 2024 at the age of 60.
- Greville was diagnosed with leiomyosarcoma, a rare and aggressive cancer that affects soft‑tissue muscle, including large veins in the body.
- Friends and family describe him as a “unique” character who once bought and drove a Japanese fire engine around North London.
- Ella has said that Greville’s death left a “huge hole” in the family and that she wants to honour his memory and raise money for the causes he would have supported.
Hendon (North London News) April 23, 2026, in memory of her uncle, Greville Marchant, who died in June 2024 at the age of 60. As reported by journalists covering the event, the 27‑year‑old clinical pharmacist from Hampstead Garden Suburb will cover the full 26.2‑mile route through the capital’s streets to honour a man described by family and friends as one of the most distinctive and generous figures in their lives.
In a profile published by The Independent, with style coverage syndicated via Yahoo News UK, Ella Marchant is quoted as saying:
“His death was hugely tragic for the whole family, he was a major figure in all of our lives. His death left a huge hole which is felt every day.”
The piece adds that the marathon will be both a personal challenge and a way to “keep his memory alive” by raising funds for charities connected to cancer and sarcoma research.
Who was Greville Marchant?
Greville Marchant, from Hendon in North London, is remembered by relatives and acquaintances for a larger‑than‑life personality and a series of unusual adventures.
As reported by the sarcoma‑awareness charity that is featuring Ella in its campaign, Greville once bought and drove a Japanese fire engine around North London, a move that became a local legend among friends and neighbours.
The charity profile notes that he was widely regarded as “unique” and “larger than life,” with relatives highlighting his sense of humour, warmth, and willingness to help others. These traits, the piece says, are now informing Ella’s motivation to run the London Marathon in his name.
Rare cancer diagnosis and its impact
Greville Marchant was diagnosed with leiomyosarcoma, a rare form of soft‑tissue sarcoma that develops in muscle tissue, including large blood vessels such as the vena cava.
As explained by the sarcoma organisation covering Ella’s story, leiomyosarcoma is often aggressive and difficult to treat, with limited public awareness despite its serious prognosis.
According to the charity’s feature, Greville’s diagnosis and subsequent illness placed a heavy emotional and physical strain on the family, particularly as he had been a central figure in their lives.
The charity’s article adds that his death in June 2024 left a “void” that relatives are still learning how to navigate, with Ella describing the loss as “tragic” and ongoing.
Ella Marchant’s training and fundraising
Ella Marchant, a clinical pharmacist working in North London, has spent months preparing for the marathon distance while balancing her professional duties.
As reported by the sarcoma‑awareness charity profile, she has been training steadily, using her background in healthcare to approach the challenge with a focus on risk‑aware preparation and injury prevention.
The charity notes that Ella is aiming to raise money for organisations that support sarcoma and cancer research, including groups that fund medical studies and provide practical support to patients and families. In the feature, she is quoted as saying that her uncle “brought light into people’s lives,” and that running the marathon is one way she can carry that spirit forward while raising awareness of a rare cancer that many people have never heard of.
What the London Marathon will mean to the family
For the Marchant family, the 2026 London Marathon is more than a sporting event; it is framed by loved‑ones as a public act of remembrance.
As the Yahoo‑syndicated profile explains, Ella’s participation is intended to ensure that Greville’s story—and the nature of the disease that took his life—does not fade from public view.
Relatives and friends quoted in the article say that Greville’s diagnosis highlighted how little information is available about leiomyosarcoma, and that Ella’s fundraising is, in part, an attempt to address that gap.
The charity piece concludes that the marathon will be both a tribute to Greville’s character and a step towards increasing awareness and research funding for a rare cancer that affects relatively small numbers of people but can be devastating when it appears.
Background of the development
Leiomyosarcoma is classed as a rare soft‑tissue sarcoma, typically arising in smooth muscle such as the walls of blood vessels, the uterus, or the gastrointestinal tract.
Because it is uncommon, it receives less public attention and funding compared with more common cancers, which has led to the formation of specialist charities and research initiatives focused specifically on sarcoma and leiomyosarcoma.
Organisations such as the National Leiomyosarcoma Foundation and the Slay Sarcoma Research Initiative have run awareness and fundraising campaigns, including annual runs and walks, to channel resources into research and patient support.
Those campaigns are often tied to larger running events, including major city marathons, where individual runners like Ella Marchant can link their personal stories to broader fundraising and awareness goals.
Within the context of the London Marathon, participants frequently choose charities that have personal significance to them, and many are supported by employer‑linked fundraising pages or charity‑specific profiles. Ella Marchant’s participation follows this pattern, with her family and the charity emphasising that her run is both a private tribute to Greville and a contribution to a wider effort to understand and treat leiomyosarcoma.
Prediction: How this development may affect audiences
For the local community in Hendon and surrounding North London areas, Ella Marchant’s story may increase awareness of leiomyosarcoma and of the role that individual fundraising can play in supporting rare‑disease research. If her profile is amplified by local media and social‑media coverage linked to the marathon, neighbours and acquaintances may be prompted to donate, participate in related events, or seek information about sarcoma symptoms and support services.
Within the wider London running community, Ella’s participation could encourage other runners with personal connections to cancer or sarcoma to align their marathon entries with specialist charities, rather than more general health causes. This shift may help channel more targeted funding to organisations that study and support patients with leiomyosarcoma, especially if her story is used in broader charity campaign materials distributed via the London Marathon’s official channels.
